title: The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids.
abstract: OBJECTIVE
  To evaluate the effect of maternally derived antibody on the immunogenicity and reactogenicity of acellular (DTaP) or whole-cell (DTP) pertussis vaccine with diphtheria and tetanus toxoids combined.
  
  
  METHODS
  A total of 2342 infants were randomized to receive one of 13 DTaP or 2 DTP vaccines at 2, 4, and 6 months of age. The correlation between preimmunization and postimmunization antibody after three doses of vaccine and the relation between preimmunization antibody and adverse reactions after the first immunization were modeled by linear regression.
  
  
  RESULTS
  After DTP but not DTaP, higher levels of preexisting antibody were associated with substantial (28% to 56%) reductions in the subsequent antibody response to pertussis toxin (PT). For other pertussis antibodies, modest inverse correlations were seen between preexisting antibody concentrations and most postimmunization antibody responses (resulting in 8% to 18% reductions in postimmunization antibody) for both DTP and DTaP. There was no consistent association in any DTP or DTaP group between adverse reactions and preimmunization antibody levels.
  
  
  CONCLUSIONS
  The PT antibody response to DTaP, unlike DTP, is not adversely affected by preexisting antibody to PT. Inhibitory effects with respect to other antibodies, seen with both DTP and DTaP, were relatively modest. Our data suggest that the use of acellular pertussis vaccines in adults, which could confer higher levels of antibody in women before pregnancy, would be unlikely to adversely affect pertussis antibody responses after DTaP among infants born to mothers with high antibody levels.
authors.affiliation: Department of Microbiology and Immunology, Baylor College of Medicine, Houston, TX 77030, USA.
authors.forename: J A
authors.initials: JA
authors.lastname: Englund
authors.forename: E L
authors.initials: EL
authors.lastname: Anderson
authors.forename: G F
authors.initials: GF
authors.lastname: Reed
authors.forename: M D
authors.initials: MD
authors.lastname: Decker
authors.forename: K M
authors.initials: KM
authors.lastname: Edwards
authors.forename: M E
authors.initials: ME
authors.lastname: Pichichero
authors.forename: M C
authors.initials: MC
authors.lastname: Steinhoff
authors.forename: M B
authors.initials: MB
authors.lastname: Rennels
authors.forename: A
authors.initials: A
authors.lastname: Deforest
authors.forename: B D
authors.initials: BD
authors.lastname: Meade
mesh_terms: D000907:Antibodies, Bacterial / Q000097:blood*; D001886:Bordetella pertussis / Q000276:immunology*; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000009:adverse effects / Q000276:immunology*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007112:Immunity, Maternally-Acquired / Q000276:immunology; D007223:Infant; D016014:Linear Models; D010567:Pertussis Vaccine / Q000009:adverse effects / Q000276:immunology*; D014917:Whooping Cough / Q000276:immunology*
chemical_list: D000907:Antibodies, Bacterial; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D010567:Pertussis Vaccine